Latest MetaStat Inc. Stories
NEW YORK, April 23, 2013 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued a Quarterly Update on MetaStat, Inc. (OTCBB: MTST). The Quarterly Update summarizes MetaStat's recent financial results and highlights key accomplishments that have occurred since the base Executive Informational Overview(®) (EIO) was published on January 3, 2013. Both MetaStat's Quarterly Update and base EIO can be found at www.crystalra.com. MetaStat, Inc. ("MetaStat" or...
MONTCLAIR, N.J., April 15, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today the appointment of David Epstein, Ph.D. as Advisor for MetaStat's Drug Discovery & Development efforts. In addition, MetaStat intends to appoint Dr. Epstein to MetaStat's board of directors as soon as practicable. Dr. Epstein brings tremendous expertise to MetaStat at a pivotal time in the company's evolution....
MONTCLAIR, N.J., Feb. 26, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, announced today that the Company has been granted eligibility status by the Depository Trust Corporation ("DTC") as of February 20, 2013. DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies....
MONTCLAIR, N.J., Jan. 18, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, today announced that the Company will be presenting at the NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference held at the Hard Rock Hotel & Casino, Hollywood, Florida, on Tuesday, January 22, 2013 at 4:30 p.m. Eastern Time. Dr. Oscar Bronsther, Chief Executive Officer...
NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(®) (EIO) on MetaStat, Inc. (MTST-OTC.BB). The full 52-page report can be found at www.crystalra.com. MetaStat, Inc. ("MetaStat" or "the Company") develops next-generation diagnostic and therapeutic products for metastatic cancer--cancer that has spread from a primary tumor to other areas of the body. The Company's pipeline is based on over 15...
MONTCLAIR, N.J., Jan. 7, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, announced today that a 500 patient trial in breast cancer has been completed. The trial was completed on time and on budget in line with previously disclosed expectations and the company expects the full analysis and publication of the data later in the year. According to Dr. Oscar Bronsther,...
MONTCLAIR, N.J., Jan. 3, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCQB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis today announced that Warren C. Lau, President of MetaStat, will be presenting at the Biotech Showcase conference in San Francisco on Monday, January 7, 2013. The presentation schedule is as follows: Conference: Biotech Showcase 2013Date: Monday, January 7, 2013Location: Parc 55 WyndhamTime: 3:45...
MONTCLAIR, N.J., Dec. 4, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that John S. Condeelis, Ph.D., Chairman of MetaStat's Scientific Advisory Board, and Joan Jones, M.D., a member of MetaStat's Clinical Advisory Board, will be presenting data on the Company's licensed metastatic breast cancer markers at the CTRC-AACR 2012 San Antonio Breast Cancer...
MONTCLAIR, N.J., Nov. 26, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST) today announced the October 31, 2012 online publication of "Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients" in Breast Cancer Research, an international, peer-reviewed online journal. Dr. John S. Condeelis, Chairman of MetaStat's Scientific Advisory Board, is senior on the publication. Dr. Condeelis holds...
MONTCLAIR, N.J., Nov. 14, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on the development and commercialization of proprietary clinical diagnostics that predict the probability of systemic hematogenous (blood borne) metastasis, as well as companion therapeutics to prevent this deadly spread, today announced that its common stock has been approved for quotation on the OTC Bulletin Board ("OTCBB") commencing with the...
